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Abstract 29 
 30 
Patient Empowerment Programme (PEP) in primary care was effective in preventing 31 
diabetes-related complications in patients with diabetes. Nevertheless, the effect of PEP on 32 
glycaemic control, weight control, and complications was unclear in obese type 2 diabetic 33 
patients. We aimed to assess whether PEP reduced all-cause mortality, first macrovascular 34 
and microvascular disease events. A cohort of 6,372 obese type 2 diabetic patients without 35 
prior occurrence of macrovascular or microvascular disease events on or before baseline 36 
study recruitment date was linked to the administrative database from 2008 to 2013. Non-37 
PEP participants were matched one-to-one with the PEP participants using propensity score 38 
method with respect to their baseline covariates. Cox proportional hazard regressions were 39 
performed to estimate the associations of the PEP intervention with the occurrence of first 40 
macrovascular or microvascular disease events and death from any cause, controlling for 41 
demographic and clinical characteristics. During a median 31.5 months of follow-up, 350 42 
(PEP/non-PEP: 151/199) patients suffered from a first macrovascular or microvascular 43 
disease event while 93 patients (PEP/non-PEP: 34/61) died from any cause. After adjusting 44 
for confounding variables, PEP participants had lower incidence rates of all-cause mortality 45 
(hazard ratio (HR): 0.589, 95% confidence interval (CI) 0.380-0.915, P=0.018) and first 46 
macrovascular or microvascular disease events (HR: 0.782, 95% CI 0.632-0.968, P=0.024) 47 
than those with PEP. Enrolment to PEP was an effective approach in reducing all-cause 48 
mortality and first macrovascular or microvascular disease events in obese patients with type 49 
2 diabetes. 50 
 51 
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Manuscript Text 56 
 57 
Introduction 58 
 59 
Type 2 diabetes mellitus (T2DM) and obesity are evolving pandemics that had increased 60 
risk of developing comorbidities and complications, and thus imposed major health and 61 
economic burden to health care system worldwide [1]. Since 1970s, the term ‘diabesity’ has 62 
coined to describe the individuals with co-occurrence of diabetes and obesity, in which they 63 
had pathogenic inter-relationship [2]. Obesity confers one of the major risk factors of T2DM 64 
[3] and diabetes-related complications including macro- and microvascular diseases [4]. 65 
Nowadays, the vast majority of T2DM patients reported to be obese in the US where obesity 66 
was highly prevalent [5].  67 
 68 
There were much evidence for the benefits of modest weight loss, equivalent to 5-10% loss 69 
of total body weight, in obese patients with T2DM[6,7]. Despite well-established benefits of 70 
weight loss, controversies are being focused on the optimal approaches for achieving 71 
treatment goals of weight management. Towards the means of effective management of 72 
obese T2DM patients, narrative reviews [2,6] have consolidated a broad range of therapeutic 73 
approaches including surgical approach via bariatric surgery, pharmacologic approach via 74 
anti-obesity and incretin-based anti-diabetic medications, and non-surgical-pharmacologic 75 
approach via intensive lifestyle modification. Still, conventional approach of community-76 
based education and support in promoting healthy lifestyle and behavioural changes is one 77 
of the key strategies for improving the standard of diabetes care in primary care setting [8].  78 
 79 
Currently, structured self-management education provides one of the most reliable pathways 80 
to sustained empowerment and healthy behavioural changes in diabetic patients managing 81 
their own condition[9]. Clinical benefit of structured diabetes education program delivered 82 
in a group or individual basis has been confirmed in systematic reviews [10-13] and meta-83 
analyses [14-16], and resulted in significant improvements in weight control, glycemic 84 
control and cardiovascular risk factor control. Although the explicit changes in body weight 85 
after structured diabetes education have been well recognized in clinical trials, whether 86 
structured education would be associated with modest weight loss and a lower risk of 87 
macrovascular and microvascular complications remains questionable in ‘real-world’ setting. 88 
 89 
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Notably, recent studies [17-21] examined the effects on glycemic control, quality of life and 90 
incidence of cardiovascular events and microvascular events of structured diabetes education 91 
program, Patient Empowerment Programme (PEP), versus the usual clinical practice in 92 
primary care setting. As yet, no randomised controlled trials, or population-based 93 
observational cohort studies have been conducted to investigate the effect of structured 94 
education on weight control, diabetes-related complications in diabesity patients. 95 
Furthermore, diabesity patients who enrolled to PEP have access to additional weight 96 
management program with exercise and nutrition empowerment sessions offered by trained 97 
dietitians and physiotherapists. Nevertheless, no prior studies explored the effect of dual 98 
program use on the diabesity patients, in which the effectiveness may be strengthened or 99 
hampered.  100 
 101 
The main aim of this study was to test in a population-based propensity-matched cohort 102 
study on whether this structured diabetes education program in primary care promoted 103 
greater benefits on metabolic control and reduced macro- and microvascular diseases in 104 
patients with diabesity. The exploratory aim was to evaluate whether weight management 105 
program would improve macro- and microvascular diseases among diabesity patients who 106 
have attended PEP. We hypothesized that diabesity patients with PEP attendance were more 107 
effective than those without, and dual use of PEP and weight management program yielded 108 
additional benefits when compared to standalone participation of PEP.  109 
 110 
Methods 111 
 112 
In 2010, the Hong Kong Hospital Authority has launched the Patient Empowerment 113 
Programme (PEP) which provided tertiary wide primary care service to the patients. PEP is 114 
a structured education programme which aims to enhance the quality of chronic disease 115 
management, to equip participants with the knowledge, skills and self-awareness of their 116 
own disease condition and to promote autonomous self-regulation to maximise their 117 
potential for health and well-being. Through structural health education including skill 118 
transfer, self-efficacy enhancement, mutual support groups, targeted treatment plan and 119 
weight management, participants’ lifestyle modification and risk factor management could 120 
be enhanced effectively. Several medical experts in the non-government organisations 121 
organised 6-7 PEP sessions (2 disease-specific sessions and 4-5 generic sessions) on 122 
structural health education, disease-specific knowledge and lifestyle modification and post-123 
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program follow-ups to enhance and maintain the participants’ self-management. The total 124 
contact time of disease-specific and generic sessions is 8-10 hours (2 hours per session) and 125 
5 hours (2.5 hours per session), respectively. Disease-specific components were delivered by 126 
experienced nurses through lecture-based learning sessions covering comprehensive 127 
information about diabetes, responsibility of self-care management, medications in diabetes 128 
control, and contingency management on hypo- and hyper-glycaemia. Each generic 129 
component session covers the importance of self-management and behaviour modification, 130 
healthy diet and regular exercise goal setting and problem-solving skills, sharing on self-131 
monitoring experience, stress coping management, psychosocial support and networking, 132 
and communications with healthcare professionals. A detailed PEP setting and mode of 133 
education delivery has been described in the previous study[17-21]. This study included 134 
patients attended at least one session of PEP dated between 1 March, 2010 and 30 June, 135 
2012.  136 
 137 
Subjects 138 
 139 
All patients with T2DM were sampled from a population-based cohort of patients attended 140 
the general outpatient clinics in Hong Kong Hospital Authority, the largest public health 141 
service provider in Hong Kong. The outcome evaluation included all obese patients (Body 142 
mass index ≥ 27.5 kg/m2 [22] at baseline) with T2DM who had attended at least one PEP 143 
session. The T2DM subjects were identified with the International Classification of 144 
Primary Care-2 (ICPC-2) code of ‘T90’, through the clinical management system database 145 
of Hong Kong Hospital Authority. A total of 4,254 Diabesity subjects who had enrolled 146 
into PEP and attended at least one PEP session between 1 March, 2010 and 31 March, 147 
2012 were included in the evaluation of the incidence in macro- and microvascular events. 148 
Out of 41,775 Diabesity subjects (PEP: 4,254, non-PEP: 37,221) within the database, 149 
4,395 subjects (PEP: 326, non-PEP: 4,069) were excluded due to the prior diagnosis of 150 
macrovascular or microvascular diseases before baseline. Each patient was observed from 151 
baseline until the incidence of any macrovascular or microvascular disease events, death 152 
from any cause, or date of last follow-up as censoring, or 31 December, 2013, whichever 153 
came first. To evaluate the net effect of PEP on the post-intervention, 3,186 Diabesity 154 
patients who have not ever participated in PEP on or before 31 December, 2013 were 155 
matched to PEP subjects on propensity score matching (described below) as non-PEP 156 
group.  157 
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 158 
Patients having history of co-morbidities and diagnosis of macro- and microvascular 159 
disease events were defined according to the diagnosis coding system of International 160 
Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) and 161 
International Classification of Primary Care (ICPC-2) in clinical management system 162 
database of the Hong Kong Hospital Authority. The complementary use of ICPC-2 and 163 
ICD-9-CM diagnosis coding systems were managed to identify the history of co-164 
morbidities and diagnosis of macro- and microvascular disease events in both the primary 165 
and secondary care settings. 166 
 167 
Ethics approval of this study was granted by institutional review board and clinical trial 168 
registry (NCT01935349, ClinicalTrials.gov). 169 
 170 
Macrovascular and Microvascular Diseases  171 
 172 
In the present study, four outcome events were our primary interests: 1) all-cause mortality, 173 
2) first macrovascular event including coronary heart disease (CHD), stroke, or heart 174 
failure, 3) first microvascular event including retinopathy, nephropathy or neuropathy, and 175 
4) first composite macro- and microvascular event. The incidence of CHD was defined as 176 
the earliest date of diagnosis with either ICPC-2 of K74-K76 or ICD-9-CM of 410.x-414.x 177 
or 798.x. The incidence of stroke was defined as the earliest date of diagnosis with either 178 
ICPC-2 of K89-K91 or ICD-9-CM of 430.x-438.x. The incidence of heart failure was 179 
defined as the earliest date of diagnosis with either ICPC-2 of K77 or ICD-9-CM of 428.x. 180 
The incidence of retinopathy was defined as the earliest date of diagnosis with either 181 
ICPC-2 of F83 or ICD-9-CM of 249.5x, 362.03-362.06 or 366.41. The incidence of 182 
nephropathy was defined as the earliest date of diagnosis with ICD-9-CM of 249.4x, 183 
250.40-250.43, 581.x-585.x or 791.0. The incidence of neuropathy was defined as the 184 
earliest date of diagnosis with either ICPC-2 of N94 or ICD-9-CM of 249.6x, 250.6x, 185 
337.1, 355.x or 357.2.  186 
 187 
Baseline Covariates 188 
 189 
Demographic, biometric data and disease characteristics, and treatment modalities and 190 
enrolment of co-intervention [23] for diabetes at baseline were treated as the covariates of 191 
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patients. Demographic characteristics of patients included sex, age, smoking status, alcohol 192 
status, and educational level. Biometric data included body mass index (BMI), hemoglobin 193 
A1c (HbA1c) level, blood pressure (BP), lipid profile, triglyceride and estimated glomerular 194 
filtration rate (eGFR) on the date within three-month period of baseline. Disease 195 
characteristics included the duration of T2DM, history of hypertension, family history of 196 
T2DM, insulin, oral anti-diabetic drugs, anti-hypertensive drugs and lipid-lowering agents 197 
used, Charlson Comorbidity Index[24] and the enrolment of co-intervention. 198 
 199 
Propensity Score Matching 200 
 201 
A propensity score is the conditional probability of being intervention given the observed 202 
covariates [25]. The technique aims to form comparable PEP intervention and non-PEP 203 
groups by logistic regression with relevant baseline characteristics of each patient 204 
summarized into a single-index variable (the propensity score) and match patients in the non-205 
PEP comparison pool to patients in the PEP intervention group based on the value of the 206 
propensity score [26-28]. Correspondingly, the propensity score was generated for each 207 
patient, modelling  PEP intervention as a dependent variable and baseline covariates of 208 
patients (including sex, age, smoking status, alcohol status, educational level, HbA1c level, 209 
BMI, BP, triglyceride, total cholesterol-to-high density lipoprotein cholesterol ratio, low 210 
density lipoprotein cholesterol, eGFR, the level of duration of T2DM, history of hypertension, 211 
family history of diabetes mellitus, the use of insulin, oral anti-diabetic drugs, hypertensive 212 
drugs and lipid-lowering agent, Charlson Comorbidity Index and enrolment of co-213 
intervention for diabetes) as independent variables. The propensity score mapping was made 214 
by using the “psmatch2” command [29] with the nearest neighbour without replacement 215 
approach in the STATA.  216 
 217 
Data Analysis 218 
 219 
Descriptive statistics were used to calculate the baseline characteristics of demographic 220 
and clinical data in PEP and non-PEP groups after propensity score matching. Differences 221 
in baseline characteristics between PEP and non-PEP groups were tested for matched-pairs 222 
[30] using independent t-test for continuous variables or chi-square test for categorical 223 
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variables. Independent t-test was used to assess the differences in HbA1c, systolic BP, 224 
diastolic BP, LDL-C and BMI between PEP and non-PEP groups at different time points. 225 
The cumulative incidence rate and incidence rate of all-cause mortality, macrovascular and 226 
microvascular disease events with the corresponding 95% confidence interval (CI) were 227 
reported in both groups based on the assumption that the observed incident cases followed 228 
a Poisson distribution. 229 
 230 
Multivariable Cox proportional hazards regression was performed to estimate the effect of 231 
PEP on the dependent variable of macrovascular event, microvascular event, first 232 
composite event and all-cause mortality, accounting for all baseline characteristics of 233 
patients. For each model, survival curves were estimated by Kaplan-Meier method and 234 
their differences between PEP and non-PEP groups were compared using the log-rank test. 235 
Hazard ratio (HR) and the corresponding 95% CI were reported for each variable in the 236 
regression models. Predictive accuracy of Cox models was assessed and compared using 237 
Harrell’s discrimination C-index, ranging from zero to one. A value of 0.5 indicates no 238 
predictive discrimination, and values of 0 or 1.0 indicate perfect separation of patients [31]. 239 
Goodness-of-fit of Cox regression model were assessed using Akaike information criterion 240 
and Bayesian information criterion. Similar analyses were pursued on the subgroup 241 
analysis of the effect of weight management on dependent variables among PEP 242 
participants. 243 
 244 
All statistical analyses were performed using STATA Version 13.0. All significance tests 245 
were two-tailed and those with a p-value less than 0.05 were considered statistically 246 
significant. 247 
 248 
Results 249 
 250 
Table 1 shows cohort baseline characteristics after 1:1 propensity score matching. Out of 251 
4,254 diabesity subjects, 3,186 (74.9%) were successfully matched with non-PEP 252 
participants using the demographic and clinical characteristics. As expected, the two 253 
groups had similar baseline demographic and clinical characteristics, as indicated in the 254 
insignificance of all the p-values (≥ 0.05).  255 
 256 
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Comparisons of PEP and non-PEP participants in five of the clinical parameters (HbA1c, 257 
systolic BP, diastolic BP, LDL-C and BMI) at different time points are displayed in Figure 258 
1. Both groups did not show any significant difference in all of the parameters at baseline 259 
but PEP participants had smaller means in all clinical measurement after baseline by 260 
observation, when compared with non-PEP participants. 261 
 262 
Table 2 and Figure 2 present Kaplan-Meier survival curves and the number of all-cause 263 
mortality, macro- and microvascular disease, and composite events at a median follow-up 264 
of 29.5 to 31.5 months (range, 0.5 to 46.5 months). PEP participants generally suffered 265 
from fewer death, macro- and microvascular disease events than the non-PEP participants. 266 
Specifically, 95 deaths (34 PEP participants and 61 non-PEP participants) were resulted 267 
during a total of 8,200 person-years for PEP groups and 8,164 person-years for non-PEP 268 
groups. In addition, 350 first macrovascular or microvascular disease events (151 PEP 269 
participants and 199 non-PEP participants) occurred during a total of 7,972 person-years 270 
for PEP participants and 7,926 person-years for non-PEP participants. This also coincides 271 
with the results obtained if macrovascular or microvascular disease events were 272 
considered individually. 273 
 274 
Multivariable Cox Regression Analysis 275 
 276 
Multivariable Cox regression analyses of all-cause mortality, macro- and microvascular 277 
disease events as dependent variables are shown in table 3. After adjusting for 278 
confounding variables, PEP participants had a lower incidence rate of all-cause mortality 279 
than the non-PEP participants (HR: 0.589, 95% CI 0.380-0.915; P=0.018). Log-rank test 280 
further suggested that there was a significant difference in the survival times between the 281 
two groups (chi-square statistic=8.47; P=0.004). Additionally, a lower risk of first 282 
macrovascular or microvascular disease event was observed among the PEP groups than 283 
the non-PEP groups (HR: 0.782, 95% CI 0.632-0.968; P=0.024) and the difference in 284 
survival time was significant (chi-square statistic=5.82; P=0.016). However, if the 285 
macrovascular or microvascular disease events were studied alone, those two groups were 286 
not significantly different in incidence rates (macrovascular diseases: HR: 0.828, 95% CI 287 
0.619-1.108; P=0.205; microvascular diseases: HR: 0.761, 95% CI 0.567-1.021; P=0.069).  288 
 289 
Subgroup Analysis 290 
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 291 
Among those 3,186 PEP participants, 94.0% (n=2994) had not participated in the weight 292 
management program. A higher risk of death, but not statistically significant, was 293 
observed among PEP participants who participated the weight management program than 294 
those who did not (HR: 1.824, 95% CI 0.516-6.442; P=0.351). This result was further 295 
confirmed by the corresponding log-rank test (chi-square statistic=0.13; P=0.716). 296 
Moreover, participation of weight management program was not associated with a lower 297 
incidence risk of macrovascular or microvascular disease events (HR: 0.861, 95% CI 298 
0.420-1.765; P=0.682). Similar findings were obtained for the incidence of macrovascular 299 
and microvascular disease events individually. 300 
 301 
Discussions 302 
 303 
The major findings in this propensity matched cohort study revealed that lower composite 304 
macro- and microvascular complication and all-cause mortality were associated with PEP 305 
participation in a median of 31.5 months. Compared with non-participants, PEP 306 
participants had a reduction in composite macro- and microvascular complication by one-307 
quarter (PEP/non-PEP: 151/199, HR=0.782) and all-cause mortality by half (PEP/non-PEP: 308 
34/61, HR=0.589), after adjusting for demographic and clinical characteristics. Results of 309 
structured education program were promising, having reduced occurrence of death from 310 
any cause and diabetes-related complication events, mainly attributable to the sustainable 311 
improvement in glycemic control at various follow-up assessments. Moreover, the 312 
additional component of weight management program was not associated with a 313 
significant reduction in the mortality, macro- and microvascular events in diabesity 314 
patients who attended PEP. Once diabesity patients had participated weight management 315 
program in addition to PEP, effectiveness may be reduced due to potentially excessive 316 
intervention.  317 
 318 
Macro- and microvascular complications have seldom been reported in the structured 319 
diabetes education literature. Besides evidence of prior observational studies from PEP 320 
[18,19], the role of structured diabetes education in the incidence of macro- and 321 
microvascular complication has only been investigated in the cost-effectiveness analysis of 322 
diabetes education and self-management for ongoing and newly diagnosed (DESMOND) 323 
[32], using the Sheffield Type 2 Diabetes Model for the long-term incidence of macro- and 324 
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microvascular complications. It was worthwhile noting that the Sheffield Type 2 Diabetes 325 
Model replicated the predicted risk of macro- and microvascular complications among 326 
T2DM patients, indicating that the effects of structured diabetes education on observed 327 
events of microvascular complication have not been shown in the literature. The results of 328 
current study investigated not only the effects of PEP on observed composite complication 329 
events, but also the effects of PEP on observed composite macro- and microvascular 330 
events. Interestingly, the decreased risk for composite events for PEP participants 331 
compared with non-PEP participants was mainly driven more by the occurrence of 332 
microvascular events and less by the occurrences of macrovascular events. Although there 333 
was no evidence of a significant reduction in macrovascular events or microvascular 334 
events separately among PEP group compared with non-PEP group, the incidence of 335 
microvascular event might play an slightly more important role on incidence of composite 336 
events in PEP patients.  337 
 338 
Comparison with previous studies 339 
 340 
It was noteworthy to compare findings of current study with previous studies which 341 
investigated the effects of lifestyle intervention for diabesity in the prevention and control 342 
of macro- and microvascular complications. The randomized controlled trial focusing on 343 
intensive lifestyle modification such as Look AHEAD (Action for Health in Diabetes) trial 344 
[33] demonstrated that the lifestyle intervention group had modest weight loss compared 345 
to usual care referring to diabetes education program but occurrence of cardiovascular 346 
events were not significantly less (HR=0.95, P=0.51) in lifestyle intervention group after a 347 
decade of follow-up. By contrast with lifestyle therapeutic approach, results from surgical 348 
approach significantly reduced the incidence of macro- and microvascular events. 349 
Evidence from long-term follow-up (at least 10 years) observational studies [34,35] 350 
consistently showed that bariatric surgery has considered as highly effective approach in 351 
reducing risk of macrovascular (HR=0.39-0.68) or microvascular diseases (HR=0.22-0.44) 352 
event, and composite event (HR=0.36) when compared to diabesity patients receiving 353 
usual care. Despite such effective therapeutic approach, adverse events following bariatric 354 
surgery were estimated to be 0.3%-1.0% [36] in a meta-analysis of 32 studies reporting 355 
results of bariatric surgery. 356 
 357 
Strengths and Limitations of this study 358 
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 359 
There were several strengths in this study. First, as a result of the large patient load and  360 
clinical information fully available in the administrative database of Hong Kong Hospital 361 
Authority, the study was able to carry out propensity score matching using important 362 
baseline covariates. Secondly, owing to similar culture and natural course of T2DM 363 
patients with obese in Chinese population, the results would be presumably generalizable 364 
to other Chinese populations in primary care setting. 365 
 366 
The study also had some limitations. Firstly, current study was performed as non-367 
randomized study design but instead sourced from the clinical data of routine clinical 368 
practice in ‘real-world’ setting. For instance, those who joined PEP may have more health 369 
consciousness and motivation compared to those who did not join. We cannot rule out the 370 
possibility that PEP participants tended to have better skills and self-awareness, resulting 371 
in lower incidence of macro- and microvascular complications. These baseline 372 
characteristics were not measurable to isolate the effect of confounding variables on the 373 
outcomes. To adjust for confounding variables, the administrative database was lacking in 374 
the lifestyle and psycho-social factors such as quality of life and self-efficacy measures, 375 
which might result in less robust control for the unbalanced baseline covariates when 376 
selecting controls through propensity score matching.  377 
 378 
Conclusion 379 
 380 
Results of this propensity score matched cohort study provided evidence that structured 381 
diabetes education program was an effective approach in reducing not only HbA1C levels 382 
but also all-cause mortality and first microvascular or microvascular disease events in 383 
diabesity patients. However, dual use of structured education program and weight 384 
management program was not associated with reduction in event occurrences, partly due 385 
to potentially excessive program intervened on diabesity patients.  386 
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Figure 1 Comparisons of PEP and non-PEP participants in HbA1c, SBP, DBP, LDL-C and BMI at baseline, 12-
month, 24-month and 36-month follow-up 
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Figure 2 Kaplan-Meier Survival Curves for All-cause Mortality, Macrovascular and Microvascular Disease 
Events 
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Table 1. Socio-demographic and Clinical Characteristics 
 
PEP Participants vs non-PEP Participants PEP Participants   
Factor 
Total (N=6,372) 
% (N) 
PEP (N=3,186) 
% (N) 
Non-PEP (N=3,186) 
% (N) 
P-value 
Total (N=3,186) 
% (N) 
WM attended 
(N=2,994) 
% (N) 
WM not attended 
(N=192) 
% (N) 
P-value 
Socio-demographic                 
Sex 
   
0.410 
   
0.403 
Female 61.7 (3,932) 61.2 (1,950) 62.2 (1,982) 
 
62.2 (1,982) 62.4 (1,868) 59.4 (114) 
 
Male 38.3 (2,440) 38.8 (1,236) 37.8 (1,204) 
 
37.8 (1,204) 37.6 (1,126) 40.6 (78) 
 
Age (mean±SD), year 61.60±10.64 (6,372) 61.64±9.75 (3,186) 61.57±11.47 (3,186) 0.785 61.64±9.75 (3,186) 60.49±8.93 (192) 61.71±9.79 (2,994) 0.092 
Smoking status 
   
0.755 
   
0.645 
Non-smoker 95.8 (6,103) 95.9 (3,054) 95.7 (3,049) 
 
95.7 (3,049) 95.7 (2,864) 96.4 (185) 
 
Smoker 4.2 (269) 4.1 (132) 4.3 (137) 
 
4.3 (137) 4.3 (130) 3.6 (7) 
 
Alcohol status 
   
0.803 
   
0.585 
Non-drinker 79.8 (5,084) 79.9 (2,546) 79.7 (2,538) 
 
79.7 (2,538) 79.8 (2,388) 78.1 (150) 
 
Drinker 20.2 (1,288) 20.1 (640) 20.3 (648) 
 
20.3 (648) 20.2 (606) 21.9 (42) 
 
Educational level 
   
0.379 
   
0.024* 
No formal 
education/ Primary 
53.7 (3,421) 53.1 (1,693) 54.2 (1,728) 
 
54.2 (1,728) 54.7 (1,639) 46.4 (89) 
 
Secondary/ 
Tertiary 
46.3 (2,951) 46.9 (1,493) 45.8 (1,458) 
 
16.3 (519) 16.4 (490) 15.1 (29) 
 
         
Laboratory results at baseline (mean±SD) 
       
BMI, kg/m2 30.46±2.90 (6,372) 30.45±2.91 (3,186) 30.47±2.88 (3,186) 0.835 30.45±2.91 (3,186) 31.06±3.07 (192) 30.41±2.89 (2,994) 0.003* 
HbA1c, % 7.36±1.13 (6,372) 7.36±1.09 (3,186) 7.36±1.17 (3,186) 0.876 7.36±1.09 (3,186) 7.19±0.93 (192) 7.37±1.10 (2,994) 0.023* 
Systolic blood pressure, 
mmHg 
135.92±16.04 (6,372) 135.86±16.62 (3,186) 135.98±15.43 (3,186) 0.767 135.86±16.62 (3,186) 134.35±17.07 (192) 135.96±16.59 (2,994) 0.194 
Diastolic blood 78.14±10.51 (6,372) 78.05±10.87 (3,186) 78.24±10.15 (3,186) 0.460 78.05±10.87 (3,186) 78.34±11.22 (192) 78.03±10.85 (2,994) 0.701 
 
PEP Participants vs non-PEP Participants PEP Participants   
Factor 
Total (N=6,372) 
% (N) 
PEP (N=3,186) 
% (N) 
Non-PEP (N=3,186) 
% (N) 
P-value 
Total (N=3,186) 
% (N) 
WM attended 
(N=2,994) 
% (N) 
WM not attended 
(N=192) 
% (N) 
P-value 
pressure, mmHg 
Triglyceride, mmol/L 1.76±1.06 (6,372) 1.75±0.98 (3,186) 1.77±1.12 (3,186) 0.425 1.75±0.98 (3,186) 1.83±0.94 (192) 1.74±0.99 (2,994) 0.246 
TC/HDL-C ratio 4.15±1.10 (6,372) 4.16±1.11 (3,186) 4.14±1.10 (3,186) 0.626 4.16±1.11 (3,186) 4.26±1.14 (192) 4.15±1.11 (2,994) 0.187 
LDL-C, mmol/L 2.88±0.80 (6,372) 2.89±0.81 (3,186) 2.86±0.78 (3,186) 0.179 2.89±0.81 (3,186) 2.92±0.75 (192) 2.89±0.81 (2,994) 0.583 
eGFR, ml/min/1.73m2 85.02±20.98 (6,372) 84.94±19.98 (3,186) 85.09±21.93 (3,186) 0.782 84.94±19.98 (3,186) 84.15±17.89 (192) 85.00±20.11 (2,994) 0.568 
         
clinical 
        
Duration of T2DM, 
year 
5.82±5.40 (6,372) 5.72±5.57 (3,186) 5.91±5.21 (3,186) 0.155 5.72±5.57 (3,186) 5.30±4.61 (192) 5.75±5.63 (2,994) 0.277 
Duration of T2DM, 
year    
0.583 
   
0.707 
≤5 years 60.3 (3,840) 60.4 (1,923) 60.2 (1,917) 
 
60.2 (1,917) 60.0 (1,796) 63.0 (121) 
 
5-10 years 23.1 (1,471) 22.6 (721) 23.5 (750) 
 
23.5 (750) 23.6 (708) 21.9 (42) 
 
>10 years 16.7 (1,061) 17.0 (542) 16.3 (519) 
 
16.3 (519) 16.4 (490) 15.1 (29) 
 
History of hypertension 82.9 (5,282) 82.6 (2,633) 83.1 (2,649) 0.595 83.1 (2,649) 83.5 (2,499) 78.1 (150) 0.055 
Family history of 
diabetes mellitus    
0.927 
   
0.076 
Yes 42.3 (2,697) 42.6 (1,356) 42.1 (1,341) 
 
42.1 (1,341) 42.4 (1,270) 37.0 (71) 
 
No 8.7 (554) 8.6 (275) 8.8 (279) 
 
8.8 (279) 8.9 (267) 6.3 (12) 
 
Unknown 49.0 (3,121) 48.8 (1,555) 49.2 (1,566) 
 
49.2 (1,566) 48.7 (1,457) 56.8 (109) 
 
Insulin used 1.5 (97) 1.4 (46) 1.6 (51) 0.609 1.6 (51) 1.6 (49) 1.0 (2) 0.524 
Oral anti-diabetic drugs 
used 
85.2 (5,429) 85.1 (2,712) 85.3 (2,717) 0.860 85.3 (2,717) 85.4 (2,556) 83.9 (161) 0.565 
Anti-hypertensive drugs 87.7 (5,589) 87.6 (2,792) 87.8 (2,797) 0.849 87.8 (2,797) 87.9 (2,633) 85.4 (164) 0.300 
 
PEP Participants vs non-PEP Participants PEP Participants   
Factor 
Total (N=6,372) 
% (N) 
PEP (N=3,186) 
% (N) 
Non-PEP (N=3,186) 
% (N) 
P-value 
Total (N=3,186) 
% (N) 
WM attended 
(N=2,994) 
% (N) 
WM not attended 
(N=192) 
% (N) 
P-value 
used 
Lipid lowering agents 
used 
43.1 (2,745) 43.9 (1,400) 42.2 (1,345) 0.164 42.2 (1,345) 42.0 (1,257) 45.8 (88) 0.295 
Charlson Comorbidity 
Index 
3.79±1.25 (6,372) 3.79±1.18 (3,186) 3.79±1.32 (3,186) 0.952 3.79±1.18 (3,186) 3.73±1.19 (192) 3.80±1.18 (2,994) 0.429 
Enrolment of 
co-intervention 
on/before baseline 
17.5 (1,113) 17.6 (560) 17.4 (553) 0.817 17.4 (553) 17.5 (525) 14.6 (28) 0.295 
Note: 
        
PEP = Patient Empowerment Programme; WM = Weight Management; BMI = Body mass index; HDL = High-density lipoprotein; TC = Total cholesterol; LDL = Low-density 
lipoprotein; eGFR = estimated glomerular filtration rate; T2DM = Type 2 Diabetes Mellitus  
* Significant differences (P < 0.05) by independent t-test or by chi-square test, as appropriate 
     
 
Table 2. Number and incidence rate of all-cause mortality, macrovascular and microvascular disease events at a 
median follow-up of 31.5 months 
     
 
  
  
Cumulative 
incidence 
Incidence rate (Cases/ 100 person-years) Median 
follow-up 
periods 
(Months) Event 
Cases with 
event 
Rate Estimate 95% CI* Person-years 
Total (N= 6,372) 
      
All-cause mortality 95 0.0149 0.581 (0.470,0.710) 16,364 31.5 
Composite Macrovascular or 
Microvascular Diseases 
350 0.0549 2.202 (1.977,2.445) 15,898 31.5 
Macrovascular Diseases 189 0.0297 1.172 (1.011,1.352) 16,123 31.5 
Microvascular Diseases 185 0.0290 1.147 (0.988,1.325) 16,125 31.5 
PEP Participants (N=3,186) 
      
All-cause mortality 34 0.0107 0.415 (0.287,0.579) 8,200 30.5 
Composite Macrovascular or 
Microvascular Diseases 
151 0.0474 1.894 (1.604,2.221) 7,972 29.5 
Macrovascular Diseases 82 0.0257 1.015 (0.807,1.260) 8,080 30.5 
Microvascular Diseases 79 0.0248 0.977 (0.773,1.218) 8,087 30.5 
Non-PEP Participants (N=3,186)      
All-cause mortality 61 0.0191 0.747 (0.572,0.960) 8,164 31.5 
Composite Macrovascular or 
Microvascular Diseases 
199 0.0625 2.511 (2.174,2.885) 7,926 31.5 
Macrovascular Diseases 107 0.0336 1.330 (1.090,1.607) 8,044 31.5 
Microvascular Diseases 106 0.0333 1.319 (1.080,1.595) 8,038 31.5 
Note: 
    
 
 PEP = Patient Empowerment Programme; CI = Confidence Interval 
 
 * The 95%CI was constructed based on Poisson Distribution 
 
 
  
Table 3. Multivariable Cox proportional hazard regression on the dependent variable of all-cause mortality, macrovascular  
and microvascular disease events, adjusted for the socio-demographic and clinical characteristics 
  
 
PEP factor 
AIC BIC Harrell's C-statistic 
  HR† s.e. 95%CI P-value 
PEP Participants vs non-PEP Participants (N= 6,372) 
     
All-cause mortality 0.589 0.132 (0.380,0.915) 0.018* 1,420 1,589 0.896 (0.866,0.927) 
Composite Macrovascular or 
Microvascular Diseases 
0.782 0.085 (0.632,0.968) 0.024* 5,889 6,058 0.700 (0.670,0.729) 
Macrovascular Diseases 0.828 0.123 (0.619,1.108) 0.205 3,139 3,308 0.751 (0.714,0.789) 
Microvascular Diseases 0.761 0.114 (0.567,1.021) 0.069 3,101 3,270 0.706 (0.665,0.747) 
 
WM factor 
AIC BIC Harrell's C-statistic 
  HR† s.e. 95%CI P-value 
PEP with WM session attended vs PEP without WM session attended (N= 3,186) 
  
All-cause mortality 1.824 1.174 (0.516,6.442) 0.351 453 604 0.916 (0.870,0.962) 
Composite Macrovascular or 
Microvascular Diseases 
0.861 0.315 (0.420,1.765) 0.682 2,348 2,499 0.697 (0.654,0.741) 
Macrovascular Diseases 1.198 0.515 (0.516,2.783) 0.675 1,266 1,417 0.759 (0.703,0.815) 
Microvascular Diseases 0.402 0.290 (0.098,1.650) 0.206 1,230 1,381 0.716 (0.659,0.773) 
Note: 
    
   WM = Weight Management; PEP = Patient Empowerment Programme; HR = Hazard Ratio; 
  CI = Confidence Interval; AIC = Akaike information criterion; BIC = Bayesian information criterion 
 † HR > 1 indicates greater risk for event 
      
* Significant difference (P < 0.05) 
       
 
